Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, 3-Period Crossover Study Followed by 1 Open-label Comparator Period to Evaluate Central Nervous System Pharmacodynamic Activity of TAK-653 in Healthy Volunteers Using Transcranial Magnetic Stimulation

To see complete record on, please visit this link

Id: NCT03792672

Organisation Name: Neurocrine Biosciences

Overal Status: Completed

Start Date: February 11, 2019

Last Update: March 19, 2021

Lead Sponsor: Neurocrine Biosciences

Brief Summary: The primary purpose of this study is to determine whether TAK-653, in comparison to placebo, increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy participants.

  • Healthy Volunteers

Total execution time in seconds: 0.24925994873047